This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LOS ANGELES, CA -- (Marketwire) -- 03/22/11 -- Fresh Start Private (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, announced today that it is processing over $1 Million dollars in insurance claims at its Orange Country clinic for the month of February 2011.
Some of the insurance providers Fresh Start Private has been working with include Healthnet, Blue Cross, Cigna, Kaiser, United Healthcare, Aetna, Anthem, SSI, Tri-West, MSI and Presbyterian.
Fresh Start Private (FSP) is the only alcohol treatment program to offer a single-administration, licensed long-acting, Naltrexone implant procedure. Naltrexone has been approved for use by the FDA within the United States for the treatment of alcohol.
Naltrexone helps patients overcome urges to abuse alcohol by blocking the euphoric effects. While some patients do well with the oral formulation, there is a drawback in that it must be taken daily, and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Fresh Start Private's clients are treated with a slow release dose that lasts for a year, which gives the Company a higher success rate in the treatment of alcoholism.
The company notes that the numbers contained in this release are unaudited, and are made in good faith and based on all the financial information available to the company today. Further, past financial business, operations and stock performance are not necessarily indicative of the company's future performance.
About Fresh Start Private
Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has licensed a highly effective treatment that delivers target therapeutic levels of Naltrexone that significantly reduce patients' cravings for alcohol.
Please visit www.freshstartprivate.com
Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "optimizing," "potential," "anticipate," "goal," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission.
Investor Relations Bill Clayton Toll Free (877) 521-CEYY (2399) Email Contact